Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ontario, Canada.
Can J Psychiatry. 2012 Sep;57(9):523-9. doi: 10.1177/070674371205700902.
Prenatal serotonin reuptake inhibitor exposure is common and neonatal outcomes vary greatly, often leading to confusion about whether to use or even continue antenatal use of these antidepressants. Importantly, some but not all infants are affected, which raises questions about how maternal drug metabolism contributes to fetal drug exposure. To address this key question, our paper reviews the role of key maternal, fetal, and placental pharmacokinetic, metabolic, and genetic factors that affect the extent of fetal drug exposure. Considering the role of these factors may further our understanding of variables that may assist in optimizing maternal psychopharmacotherapy during pregnancy and neonatal outcomes.
产前选择性 5-羟色胺再摄取抑制剂（SSRIs）暴露较为常见，新生儿结局差异较大，这往往导致医生对是否使用甚至继续产前使用这些抗抑郁药感到困惑。重要的是，一些但不是所有的婴儿都会受到影响，这就提出了一个问题，即母体药物代谢如何影响胎儿的药物暴露。为了解决这个关键问题，我们的论文回顾了影响胎儿药物暴露程度的关键母体、胎儿和胎盘药代动力学、代谢和遗传因素的作用。考虑这些因素的作用可能有助于我们更好地理解可能有助于优化孕妇在怀孕期间使用精神药理学治疗和新生儿结局的变量。
